Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for avalglucosidase alfa

  1. Avalglucosidase alfa for treating Pompe disease (TA821)

    Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.

    Technology appraisal guidance
    Published
    24 August 2022
    View recommendations

    Sections for TA821

  2. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

    Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.

    Technology appraisal guidance
    Published
    15 August 2023
    View recommendations

    Sections for TA912